WCE 2017: Medically Facilitated Endoscopic Surgery: The Impact of One Week of Pre-operative Tamsulosin on Deployment of 16-French Ureteral Access Sheaths and Stone Free Rates
For this study, Dr. Kaler and team retrospectively reviewed all patients between January 2015 and September 2016 who underwent ureteroscopy alone or as part of a PCNL procedure. 97 total patients were included in this study. For this analysis, demographic data, Tamsulosin usage, ureteral access sheath size, deployment failure, ureteral injuries, stone free rate and complications were collected. Stone volume was calculated using the EAU stone volume formula and ureteral injuries were defined using the post-ureteroscopic lesion scale. Once this data was obtained, patients who were pretreated with Tamsulosin were compared to patients not treated with Tamsulosin.
Following analysis, there was significantly higher percentage of 16F ureteral access sheath deployment in the Tamsulosin group compared to the non-Tamsulosin patient group with no significant difference in ureteral injury. Further analysis also showed that pre-treatment with Tamsulosin significantly increased the odds for successful 16 F ureteral access sheath deployment. However, there was no statistically significant difference in stone free rates between the two groups. No statistical difference was seen in complications.
Dr. Kaler concluded that one week of pre-operative Tamsulosin was associated with an increase in 16F ureteral access sheath deployment in patients. He added that further evaluation on Tamsulosin use for medically expulsive therapy is needed.
Presented by: Kamaljot Kaler at the 35th World Congress of Endourology– September 12-16, 2017, Vancouver, Canada.
Authors: Kamaljot S. Kaler, Shoaib Safiullah, Daniel J. Lama, Roshan M. Patel, Young Ko, Zhamshid Okhunov, Jaime Landman, Ralph V. Clayman
Affiliation: University of California, Irvine
Written by: Renai Yoon, Department of Urology, University of California-Irvine